Europe - EPA:DBV - FR0010417345 - Common Stock
We assign a fundamental rating of 2 out of 10 to DBV. DBV was compared to 77 industry peers in the Biotechnology industry. Both the profitability and financial health of DBV have multiple concerns. While showing a medium growth rate, DBV is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -85.56% | ||
ROE | -142.22% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 91.34% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.08 | ||
Debt/FCF | N/A | ||
Altman-Z | -2.99 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.45 | ||
Quick Ratio | 2.45 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
EPA:DBV (9/23/2025, 11:53:13 AM)
1.634
+0.02 (+1.24%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 13.86 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.61 | ||
P/tB | 0.61 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -85.56% | ||
ROE | -142.22% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 91.34% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.08 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 42.61% | ||
Cap/Sales | 8.26% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.45 | ||
Quick Ratio | 2.45 | ||
Altman-Z | -2.99 |